MA51629A - Procédés de production, purification et formulation de conjugués anticorps-médicaments - Google Patents
Procédés de production, purification et formulation de conjugués anticorps-médicamentsInfo
- Publication number
- MA51629A MA51629A MA051629A MA51629A MA51629A MA 51629 A MA51629 A MA 51629A MA 051629 A MA051629 A MA 051629A MA 51629 A MA51629 A MA 51629A MA 51629 A MA51629 A MA 51629A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- formulation
- purification
- processes
- production
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Water Supply & Treatment (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862617021P | 2018-01-12 | 2018-01-12 | |
US201862673535P | 2018-05-18 | 2018-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51629A true MA51629A (fr) | 2020-11-18 |
Family
ID=67219931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051629A MA51629A (fr) | 2018-01-12 | 2019-01-11 | Procédés de production, purification et formulation de conjugués anticorps-médicaments |
Country Status (12)
Country | Link |
---|---|
US (2) | US11274121B2 (fr) |
EP (1) | EP3737421A4 (fr) |
JP (2) | JP7474195B2 (fr) |
KR (1) | KR20200108843A (fr) |
CN (1) | CN111587125A (fr) |
AU (1) | AU2019206587A1 (fr) |
CA (1) | CA3087993A1 (fr) |
IL (1) | IL275798A (fr) |
MA (1) | MA51629A (fr) |
SG (1) | SG11202005541QA (fr) |
TW (1) | TW201934187A (fr) |
WO (1) | WO2019140141A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY176282A (en) | 2013-08-30 | 2020-07-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
JP2018505128A (ja) * | 2014-11-19 | 2018-02-22 | イミュノジェン・インコーポレーテッド | 細胞結合剤−細胞毒性剤コンジュゲートを調製するためのプロセス |
US10077313B2 (en) | 2015-06-29 | 2018-09-18 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
CA3073191A1 (fr) * | 2017-08-14 | 2019-02-21 | Fujirebio Diagnostics, Inc. | Procede de conjugaison d'anticorps |
AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
US11396543B2 (en) | 2019-04-29 | 2022-07-26 | Immunogen, Inc. | Biparatopic FR-α antibodies and immunoconjugates |
EP3939691B1 (fr) | 2020-07-13 | 2023-11-22 | Sartorius Stedim Biotech GmbH | Dispositif d'assemblage de production de bio-conjugués |
EP4153241A4 (fr) | 2021-02-09 | 2023-12-06 | Genequantum Healthcare (Suzhou) Co., Ltd. | Dispositif et procédé de conjugaison pour la production de conjugués |
CA3220817A1 (fr) * | 2021-06-04 | 2022-12-08 | Eric WESTIN | Traitement du cancer chez des patients porteurs de fr-alpha soluble |
WO2023038067A1 (fr) * | 2021-09-08 | 2023-03-16 | 味の素株式会社 | Intermédiaire d'anticorps modifié de manière sélective sur un site, et procédé de production d'un dérivé d'anticorps qui comporte de manière sélective d'un site un groupe fonctionnel ou une substance fonctionnelle |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7811572B2 (en) | 2005-08-24 | 2010-10-12 | Immunogen, Inc. | Process for preparing purified drug conjugates |
JP2011523628A (ja) | 2008-04-30 | 2011-08-18 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
SI2437790T1 (sl) | 2009-06-03 | 2019-07-31 | Immunogen, Inc. | Konjugacijske metode |
KR102287474B1 (ko) | 2010-02-24 | 2021-08-06 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
EP3498303A1 (fr) | 2011-02-15 | 2019-06-19 | ImmunoGen, Inc. | Procédés de préparation de conjugués |
SG193996A1 (en) | 2011-03-29 | 2013-11-29 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
EP2524929A1 (fr) | 2011-05-17 | 2012-11-21 | Sanofi | Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B |
US20150306242A1 (en) * | 2012-10-04 | 2015-10-29 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
WO2016033546A1 (fr) * | 2014-08-29 | 2016-03-03 | Emd Millipore Corporation | Systèmes de filtration à écoulement tangentiel à passage unique et systèmes de filtration à écoulement tangentiel avec recirculation de rétentat |
RU2741470C9 (ru) | 2014-09-02 | 2021-04-27 | Иммьюноджен, Инк. | Способы составления композиций конъюгата антитело-лекарственное средство |
AU2015312075A1 (en) | 2014-09-03 | 2017-03-09 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US10077313B2 (en) | 2015-06-29 | 2018-09-18 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
WO2017174580A1 (fr) | 2016-04-04 | 2017-10-12 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Surveillance en temps réel de purification de produit |
CN114699922A (zh) | 2016-06-09 | 2022-07-05 | Emd密理博公司 | 径向路径过滤器元件及使用其的系统和方法 |
EP3558391B1 (fr) | 2016-12-23 | 2022-02-02 | Immunogen, Inc. | Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation |
US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
EP3624839A4 (fr) | 2017-05-17 | 2021-06-16 | Immunogen, Inc. | Schémas posologiques d'immunoconjugués anti-cd33 |
EP3431168A1 (fr) | 2017-07-19 | 2019-01-23 | Bayer Aktiengesellschaft | Élimination de médicament non lié après accouplement conjugué anticorps-médicament |
-
2019
- 2019-01-11 KR KR1020207020128A patent/KR20200108843A/ko not_active Application Discontinuation
- 2019-01-11 AU AU2019206587A patent/AU2019206587A1/en active Pending
- 2019-01-11 SG SG11202005541QA patent/SG11202005541QA/en unknown
- 2019-01-11 MA MA051629A patent/MA51629A/fr unknown
- 2019-01-11 CA CA3087993A patent/CA3087993A1/fr active Pending
- 2019-01-11 US US16/245,890 patent/US11274121B2/en active Active
- 2019-01-11 EP EP19738220.3A patent/EP3737421A4/fr active Pending
- 2019-01-11 JP JP2020538564A patent/JP7474195B2/ja active Active
- 2019-01-11 TW TW108101176A patent/TW201934187A/zh unknown
- 2019-01-11 CN CN201980007969.2A patent/CN111587125A/zh active Pending
- 2019-01-11 WO PCT/US2019/013120 patent/WO2019140141A1/fr unknown
-
2020
- 2020-07-01 IL IL275798A patent/IL275798A/en unknown
-
2022
- 2022-02-08 US US17/667,002 patent/US20220267371A1/en active Pending
-
2023
- 2023-12-18 JP JP2023212875A patent/JP2024019597A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190270769A1 (en) | 2019-09-05 |
RU2020121946A (ru) | 2022-03-10 |
JP2024019597A (ja) | 2024-02-09 |
EP3737421A4 (fr) | 2022-03-16 |
EP3737421A1 (fr) | 2020-11-18 |
IL275798A (en) | 2020-08-31 |
WO2019140141A1 (fr) | 2019-07-18 |
US11274121B2 (en) | 2022-03-15 |
CA3087993A1 (fr) | 2019-07-18 |
AU2019206587A1 (en) | 2020-08-06 |
KR20200108843A (ko) | 2020-09-21 |
CN111587125A (zh) | 2020-08-25 |
JP7474195B2 (ja) | 2024-04-24 |
JP2021510694A (ja) | 2021-04-30 |
TW201934187A (zh) | 2019-09-01 |
US20220267371A1 (en) | 2022-08-25 |
SG11202005541QA (en) | 2020-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51629A (fr) | Procédés de production, purification et formulation de conjugués anticorps-médicaments | |
DK4015003T3 (da) | Forbedret antistof-oligonukleotid-konjugat | |
MA50755A (fr) | Conjugués anticorps-médicaments mult-médicaments | |
DK3383363T3 (da) | Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande | |
MA50569A (fr) | Ensembles de remplissage-finition et procédés associés | |
MA48779A (fr) | Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation | |
IL263709A (en) | Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use | |
MA51778A (fr) | Conjugués anticorps-médicament anti-ccr7 | |
DK3319993T3 (da) | AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling | |
MA48723A (fr) | Procédé de production d'anticorps multispécifiques | |
MA45155A (fr) | Procédés de préparation d'oligomères morpholino de phosphorodiamidate | |
DK3408326T3 (da) | Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf | |
WO2015164392A8 (fr) | Nouveaux anticorps antii-rnf43 et méthodes d'utilisation | |
MA43835A (fr) | Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires | |
DK3478679T3 (da) | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme | |
MA45154A (fr) | Procédés de préparation d'oligomères | |
IL253999A0 (en) | History of tetrahydrothiazepine in cyclics used to treat neoplastic and/or infectious diseases | |
EP3471771A4 (fr) | Conjugués anticorps-médicaments ayant des dérivés d'amatoxine en tant que médicament | |
MA45183A (fr) | Procédés de préparation d'oligomères morpholino de phosphorodiamidate | |
MA49472A (fr) | Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole | |
MA52417A (fr) | Procédés de modification de composition corporelle | |
MA47511A (fr) | Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants | |
MA46865A (fr) | Compositions de caryophyllène, appareils et procédés | |
MA42423A (fr) | Procédé de préparation d'un revêtement | |
DK3773738T3 (da) | Antistof-lægemiddelkonjugater og anvendelser deraf til behandling af cancer |